

**THE ROLE OF AYURVEDIC PHYTOCONSTITUENTS AND FORMULATIONS IN
MODERN CANCER MANAGEMENT****Ksheera M.*¹, Dr. Udaya Ganesh B.², Kiran D.³, Greeshma P. Gowda⁴**¹Intern Rajeev Institute of Ayurvedic Medical Science and Research Centre, Hassan, Karnataka, India.²Professor and HOD Department of Panchakarma, Rajeev Institute of Ayurvedic Medical Science and Research Centre, Hassan, Karnataka, India.^{3,4}Intern, Rajeev Institute of Ayurvedic Medical Science and Research Centre, Hassan, Karnataka, India.***Corresponding Author: Ksheera M.**

Intern Rajeev Institute of Ayurvedic Medical Science and Research Centre, Hassan, Karnataka, India.

DOI: <https://doi.org/10.5281/zenodo.23829338>**How to cite this Article:** Ksheera M.*¹, Dr. Udaya Ganesh B.², Kiran D.³, Greeshma P. Gowda⁴. (2026). The Role of Ayurvedic Phytoconstituents and Formulations In Modern Cancer Management. World Journal of Pharmaceutical and Medical Research, 12(11), 128–131.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 24/09/2026

Article Revised on 14/10/2026

Article Published on 01/11/2026

ABSTRACT

Background: Cancer remains a premier global healthcare challenge characterized by toxic conventional treatments, drug resistance, and compromised patient quality of life. Traditional Indian medicine (*Ayurveda*) offers a holistic approach that can complement modern oncology. This review explores the mechanisms, clinical evidence, and supportive capacities of Ayurvedic drugs within the contemporary oncology paradigm. **Methods:** Literature from peer-reviewed databases (PubMed, Scopus, Google Scholar) covering classical principles and contemporary clinical/preclinical studies up to recent years was synthesized. **Results:** Key Ayurvedic botanicals—including, *Withania somnifera* (*Ashwagandha*), *Curcuma longa* (Turmeric), and formulations like *Triphala*—demonstrate distinct anticancer activities by modulating pathways related to proliferation, apoptosis, and chronic inflammation. Furthermore, they provide crucial host-directed benefits, notably mitigating chemotherapy-induced toxicities like mucositis and nausea. **Conclusion:** Integrating validated Ayurvedic drugs into standard oncological regimens offers a highly personalized, patient-centric model. However, widespread adoption requires stricter standardization, bioavailability enhancements, and rigorous, large-scale clinical trials.

KEYWORDS: *Ayurveda*, Integrative Oncology, Phytoconstituents, *Arbuda*, Chemotherapy-induced toxicity.**1. INTRODUCTION**

Cancer is a multifactorial disease defined by uncontrolled cellular proliferation, tissue invasion, and metabolic reprogramming.^[1] While conventional biomedical interventions—including surgical resection, chemotherapy, radiation and immunotherapy—effectively target malignant cells, they are frequently bottlenecked by systemic toxicities, therapeutic resistance, and a steep decline in quality of life.^[2] The high toxicity profile often leads to treatment discontinuation or sub-therapeutic dosing, directly impacting overall patient survival rates worldwide.

Historically, classical Ayurvedic texts such as the *Charaka Samhita* and *sushruta Samhita*, conceptualized neoplastic diseases under conditions analogous to

Arbuda (major neoplasms) and *Granthi* (minor neoplasms).^[3] These conditions are described as deep-seated, non-suppurative masses triggered by severe derangements of the *doshas* (biological tumors) and tissue elements (*Mamsa* and *Rakta*).^[4] In modern global healthcare, there is a resurgence of interest in integrating Ayurvedic pharmacopeia into standard oncology to achieve a dual objective: direct tumor inhibition and supportive, host-directed care that improves tolerability profiles.

Rather than operating as an isolated choice alternative, integrative oncology seeks to marry the targeted precision of modern biomedicine with the systemic, metabolic equilibrium offered by natural matrices.^[2] By cross-referencing ancient texts with multi-omic profiling,

contemporary investigators are building a molecular framework to understand how multi-component herbal formulations act synergistically across complex biological pathways.

2. Methodological Framework

This narrative review evaluates peer-reviewed observational studies, preclinical models, and modern clinical trials. Literature was surveyed utilizing targeted medical databases—including PubMed, Scopus, and the AYUSH Research Portal.

Formulations and phytoconstituents were vetted based on their strict correlation with modern biomolecular pathways and their documented capacity to alleviate standard cancer therapy side effects safely.^[3] Studies spanning the last two decades were prioritized to capture recent breakthroughs in bioavailability and herb-drug interaction profiles.

3. Mechanistic Correlation with 'Hallmarks of Cancer'

Ayurvedic drugs contain complex multi-component matrices that act synergistically on multiple molecular targets simultaneously. Rather than operating through a single synthetic receptor block, they align closely with several modern 'Hallmarks of Cancer' outlined in contemporary oncology.^[1]

Curcumin (*Curcuma longa*): Suppresses NF-κB and downregulates STAT3 signaling pathways.^[2] It directly targets tumor-promoting inflammation and cell survival networks. Clinical trials indicate it helps prolong progression in metastatic colorectal cancer when combined with conventional FOLFOX regimens.^[6]

Withaferin A (*Withania somnifera*): Induces reactive oxygen species (ROS)-mediated apoptosis and downregulates Akt/mTOR signaling to disrupt sustained proliferative signaling.^[7] It is well-documented in preclinical models for tumor regression and significantly enhances cellular immunity.

Piperine (*Piper nigrum*): Inhibits angiogenesis by downregulating VEGF expression and blocks Wnt/β-catenin signaling to limit metastatic potential.^[8] It is frequently utilized as a bio-enhancer to increase the absorption profiles of other polyphenols.

Triphala: A combination of three traditional fruits high in polyphenols and tannins.^[9] It induces cell cycle arrest and exhibits potent antioxidant scavenger properties, showing selective cytotoxic effects on tumor cell lines while sparing normal healthy tissue.

Table 1: Ayurvedic Phytoconstituents/Formulations and Their Oncological Applications.

Botanical / Formulation	Active Component	Primary Molecular Targets	Clinical / Supportive Role	Ref
<i>Curcuma longa</i> (Turmeric)	Curcumin	Suppresses NF-κB; Downregulates STAT3 signaling.	Prolongs progression-free survival When combined with FOLFOX. reduces severe radiation oral mucositis.	[2,6]
<i>Withania somnifera</i> (<i>Ashwagandha</i>)	Withaferin A	Induces ROS-mediated apoptosis; Downregulates Akt/mTOR.	Disrupts proliferative signaling, drives tumor regression in vivo, and bolsters Ojas (cellular immunity).	[7]
<i>Piper nigrum</i> (Black Pepper)	Piperine	Inhibits angiogenesis via VEGF; Blocks Wnt/β-catenin.	Limits metastatic potential and operates as a safe bio-enhancer to boost formulation absorption.	[8]
<i>Triphala</i> (Three-fruit matrix)	Polyphenols & Tannins	Induces cell cycle arrest; Potent free radical scavenger.	Exhibits selective cytotoxic actions against tumor cell lines while strictly sparing healthy host tissue.	[9]
<i>Zingiber officinale</i> (Ginger)	Gingerols & Shogaols	Modulates central & peripheral emetic neural pathways.	Highly effective adjuvant to conventional antiemetics; profoundly mitigates CINV symptoms.	[10]
<i>Glycyrrhiza glabra</i> (Licorice)	Yashti choorna fraction	Downregulates local mucosal inflammatory cascades.	Applied as oral rinses/gels to dramatically reduce severe radiation-induced oral mucositis ulceration.	[10]

4. Supportive Care and Mitigating Therapy-Induced Toxicities

One of the most immediate, evidence-based applications of Ayurvedic medicine is the management of side effects associated with aggressive chemotherapy and radiation regimens. By shielding healthy cell lineages without blunting tumoricidal mechanisms, these interventions preserve performance scores.

Chemotherapy-Induced Nausea and Vomiting (CINV): Clinical data validates *Zingiber officinale* (Ginger) as a safe, highly effective adjuvant to conventional antiemetics, substantially improving patient food intake, nutritional status, and baseline vitality during cycles.^[10]

Radiation-Induced Oral Mucositis: Systematic reviews show that oral rinses and gels containing *Curcuma longa* or specialized classical formulations like *Triphala Kwatha* and *Yashti choorna* (*Glycyrrhiza glabra*) dramatically reduce severe, debilitating mucosal ulcerations in head and neck cancer patients undergoing high-dose radiation fields.^[10] This prevents the placement of painful feeding tubes.

Gastroprotective & Hematopoietic Support: Traditional formulations help preserve mucosal lining integrity against chemical insults and combat therapy-induced anemia by stimulating digestive fire (*Agni*) and improving overall functional blood profiles.^[3] This enables patients to complete scheduled oncological protocols on time without unmanageable dose delays.

5. Ayurvedic approach to prevention of recurrence

After successful cancer treatment, management can be conceptualized around: *Rasayana chikitsa* - promotion of strength, vitality and quality of life *Agni* and *Ahara* management - maintaining proper digestion and nutrition *Dosha-prakriti* based lifestyle *Manasika chikitsa* - management of stress, anxiety and sleep *Dinacharya* and appropriate exercise Avoidance of *Nidana* / risk factors Continued oncological surveillance.

1. Rasayana chikitsa

Rasayana is the major *Ayurvedic* therapeutic concept that can be considered after completion of definitive cancer treatment. Potentially relevant classical *Rasayana* drugs include:

Amalaki, *Haritaki*, *Guduchi*, *Ashwagandha*, *Shatavari*, *Yashtimadhu*, *Pippali*, *Brahmi*, particularly where stress/sleep issues are prominent.

2. Herbo-Mineral Medicines

If discussing *Rasayana*/herbo-mineral therapy academically, examples traditionally encountered include: *Abhraka Bhasma*, *Suvarna Bhasma*, *Suvarna Malini Vasanta Rasa*, *Swarna Vasantamalati Rasayana*, Other appropriately selected *Rasayana* yogas.

3. Manasika chikitsa

Fear of recurrence, anxiety, depression and sleep disturbance are common after cancer treatment. *Ayurvedic* supportive measures can include: *Sattvavajaya chikitsa*, Meditation, *Pranayama*, *Yoga*, Appropriate counselling, Good sleep hygiene, Spiritual practices according to the patient's preference.

6. Challenges in Clinical Translation

Despite promising preclinical and early clinical data, several critical boundaries prevent seamless integration into mainstream global oncology:

1) Bioavailability: Highly active lipophilic molecules like curcumin suffer from rapid systemic clearance, poor intestinal absorption, and low serum concentration profiles.^[5] Advanced nano-formulation approaches are required.

2) Standardization: Natural variations in soil chemistry, seasonal harvesting schedules, and batch-to-batch processing create massive challenges in maintaining consistent active compound concentrations across batches.

3) Herb-Drug Interactions: Stricter pharmacokinetic profiling is mandatory to ensure specific herbal formulations do not inadvertently induce or inhibit cytochrome P450 pathways, which could alter the metabolic clearance of standard chemotherapeutic drugs.^[5]

7. DISCUSSION

Acharya Sushruta highlights the profound preventive benefits of periodic or repeated *Raktamokshana* (therapeutic bloodletting). He explicitly states that regular clearing of vitiated blood ensures the body remains free from specific metabolic, inflammatory, and encapsulated pathologies.^[11] Regular seasonal detoxification can prevent recurrence of neoplastic changes in the body.

8. CONCLUSION AND FUTURE DIRECTIONS

Ayurveda offers a highly personalized, patient-centric model that shifts focus from merely attacking a localized tumor mass to preserving host vitality (*Ojas*), modulating native immunity, and restoring homeostatic equilibrium.^[3] Future paradigms must bridge the gap between traditional wisdom and modern oncology through rigorous, double-blind, randomized controlled trials to establish a definitive, reproducible clinical database.^[4] Emerging frontiers like green nanotechnology provide an optimized path forward.

REFERENCES

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*, 2011; 144(5): 646-674.
- Aggarwal BB, Ichikawa H, Garodia P. From traditional *Ayurvedic* medicine to modern medicine: identification of therapeutic targets. *Expert Opin Their Targets*, 2006; 10(1): 87-11.
- Singh S, Chatterjee S. *Ayurvedic* concept of Cancer (*Arbuda*) and its therapeutic management. *J Ayurveda Integr Med*, 2018; 9(2): 134-142.
- Balachandran P, Govindarajan R. Cancer—an *Ayurvedic* perspective. *Pharmacol Res*, 2005; 51(1): 19-30.
- Mukerjee A, Vishwanatha JK. Formulation and characterization of curcumin-loaded PLGA nanospheres for cancer therapy. *Anticancer Res*, 2009; 29(10): 3867-3875.
- James MI, Chang J. Curcumin inhibits colorectal cancer cell proliferation by modulating standard chemotherapy signaling. *Trends Pharmacol Sci*, 2015; 36(5): 234-241.
- Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by Withaferin A. *AAPS J*, 2014; 16(5): 977-991.

8. Gorgani L, Mohammadi M, Najafpour GD. Piperine—The bioactive compound of black pepper: From isolation to formulations. *Compr Rev Food Sci Food Saf.*, 2017; 16(1): 124-140.
9. Sandhya T, Mishra KP. Cytotoxic effects of Triphala on prostate cancer cells. *Afr J Tradit Complement Altern Med.*, 2006; 3(2): 45-52.
10. Verma S, Shrivastava A. Integrative oncology: The role of Ayurvedic Bhasmas and herbs in mitigating chemotherapy side effects. *J Clin Oncol Res.*, 2020; 8(3): 112-119.
11. Sushruta Samhita Sutra Sthana, Chapter 14 (Shonita Varniya Adhyaya), Shloka 34.